GlaxoSmithKline (GSK) is one of the world’s leading research-based pharmaceutical and healthcare companies, has announced that it will freeze the prices of its vaccines for five years for developing countries that graduate from GAVI Alliance support.
By committing to offer GAVI Alliance prices for vaccines against pneumonia, diarrhoea and cervical cancer, GSK will support developing country governments as they transition to financing the full cost of their local vaccination programmes.
{iframe}http://businessdayonline.com/2014/08/gsk-commits-to-improving-access-to-vaccines/#.VARpRWRdW3g{/iframe}